Псориатическая Ониходистрофия Как Маркер Тяжести Псориаза И Сопутствующей Коморбидности

Ковалева, Ю. С.; Vedler, A. A.; Субботин, Е. А.; Грибова, Г. В.

doi:10.34822/2304-9448-2020-4-51-57

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Псориаз ногтей по сравнению с другими локализациями оказывает более выраженное негативное влияние на качество жизни пациентов [33,34], которое сами больные оценивают, как очень сильное -55,9% и чрезвычайно сильное -32,3% [35]. 93,3% больных в связи с псориатическим поражением ногтевых пластинок испытывали косметические проблемы, 58,9% отмечали затруднения в повседневной деятельности, 56,1% -в ведении домашнего хозяйства, 47,9% -в профессиональной сфере, 51,8% предъявляли жалобы на болезненность [36].…”

Section: Introductionunclassified

Therapy of netakimab in nail psoriasis

Kurdina,

Kolenko

2024

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. The nail psoriasis severity does not always correspond to the skin process intensity, but often correlates with a more severe, prolonged and aggressive course of the disease.Materials and methods. 48 adult patients (n = 48) with nail psoriasis were under observation. The severity of the psoriatic lesion of the nails was determined using the NAPSI index (Nail Psoriasis Severity Index). The assessment was carried out before the start of treatment, in the first week, and then every 4 weeks up to and including 52 weeks. The Dermatological Quality of Life Index (DLQI) were determined by questionnaires before the start of treatment, at the 12th and 52nd weeks. All patients on an outpatient basis received netakimab monotherapy at a dose of 120 mg in the form of two subcutaneous injections of 1 ml (60 mg) of the drug, each administered once a week at weeks 0, 1 and 2, then 1 time every 4 weeks. The total duration of treatment for each patient was 52 weeks. The safety of netakimab was evaluated based on the development of adverse events and local reactions to the administration of the drug.Results. The results of the study for 52 weeks showed high efficacy of netakimab. Average NAPSI score improved – 33.1% by the week 12 of treatment and – 72.3% by the week 52 compared to baseline, the quality of their life improved. During the 52 weeks of the study, there were no cases of early withdrawal due to adverse events and cases of serious adverse events.Conclusion. Based on the study results we recommend netakimab for medical use among patients with moderate and severe nail psoriasis.

show abstract

Section: Introductionunclassified

Therapy of netakimab in nail psoriasis

Kurdina,

Kolenko

2024

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Psoriatic onychodystrophy: Clinical course, diagnosis and therapeutic aspects

Taganov,

Molochkov,

Kulikova

et al. 2023

Russian Journal of Skin and Venereal Diseases

View full text Add to dashboard Cite

Psoriatic onychodystrophy is observed in about 80% of patients with psoriasis. Psoriasis can affect two nail structures ― the matrix and the nail bed. Involvement of the nail matrix in the pathological process can lead to the formation of leukonychia, thimble symptom, red spots in the area of the hole and destruction of the nail plate. On the other hand, the lesion of the nail bed is characterized by the formation of onycholysis, subcutaneous hyperkeratosis and subcutaneous hemorrhages. Nail lesions in psoriasis are accompanied by functional disorders and aesthetic defects, and also indicate a severe course of psoriasis. Treatment of psoriatic onychodystrophy includes topical medications, systemic therapy in cases accompanied by extensive skin lesions. This article is an overview of the main clinical features, diagnostic issues and evaluation methods, as well as treatment options for nail psoriasis.

show abstract

Псориатическая Ониходистрофия Как Маркер Тяжести Псориаза И Сопутствующей Коморбидности

Cited by 2 publications

References 0 publications

Therapy of netakimab in nail psoriasis

Therapy of netakimab in nail psoriasis

Psoriatic onychodystrophy: Clinical course, diagnosis and therapeutic aspects

Contact Info

Product

Resources

About